The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy

Pathology Research and Practice

Volumn 206, Issue 3, 2010, Pages 156-162

  Kawachi, Kae ^a   Sasaki, Takeshi ^a   Murakami, Ayumi ^b   Ishikawa, Takashi ^a   Kito, Ayako ^a   Ota, Ikuko ^a   Shimizu, Daisuke ^a   Nozawa, Akinori ^a   Nagashima, Yoji ^b   Machinami, Rikuo ^c   Aoki, Ichiro ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Department of Pathology   (Japan)

Author keywords

Anthracycline based neoadjuvant chemotherapy; Breast cancer; Fluorescent in situ hybridization (FISH); Immunohistochemistry; Topoisomerase II alpha (TOP2A)

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; NAVELBINE; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; PREDICTION; PROTEIN EXPRESSION;

ADULT; AGED; ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOADJUVANT THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 76949087835     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2009.10.009     Document Type: Article

References (32)

1. Arpino G., Ciocca D.R., Weiss H., Allred D.C., Daguerre P., Vargas-Roig L., et al. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res. Treat. 92 (2005) 69-75
2. Bofin A.M., Ytterhus B., and Hagmar B.M. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 14 (2003) 314-319
3. Bouchalova K., Trojanec R., Kolar Z., Cwiertka K., Cernakova I., Mihal V., et al. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma 53 (2006) 393-401
4. Cardoso F., Durbecq V., Larsimont D., Paesmans M., Leroy J.Y., Rouas G., et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int. J. Oncol. 24 (2004) 201-209
5. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70 (2001) 369-413
6. Chappuis P.O., Goffin J., Wong N., Perret C., Ghadirian P., Tonin P.N., et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J. Med. Genet. 39 (2002) 608-610
7. Charfare H., Limongelli S., and Purushotham A.D. Neoadjuvant chemotherapy in breast cancer. Br. J. Surg. 92 (2005) 14-23
8. Coon J.S., Marcus E., Gupta-Burt S., Seelig S., Jacobson K., Chen S., et al. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res. 8 (2002) 1061-1067
9. Di Leo A., Larsimont D., Gancberg D., Jarvinen T., Beauduin M., Vindevoghel A., et al. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann. Oncol. 12 (2001) 1081-1089
10. Di Leo A., Gancberg D., Larsimont D., Tanner M., Jarvinen T., Rouas G., et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 8 (2002) 1107-1116
11. Di Leo A., Tanner M., Desmedt C., Paesmans M., Cardoso F., Durbecq V., et al. p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann. Oncol. 18 (2007) 997-1003
12. Durbecq V., Paesmans M., Cardoso F., Desmedt C., Di Leo A., Chan S., et al. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol. Cancer Ther. 3 (2004) 1207-1214
13. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
14. Hicks D.G., Yoder B.J., Pettay J., Swain E., Tarr S., Hartke M., et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum. Pathol. 36 (2005) 348-356
15. Isaacs R.J., Davies S.L., Sandri M.I., Redwood C., Wells N.J., and Hickson I.D. Physiological regulation of eukaryotic topoisomerase II. Biochim. Biophys. Acta 1400 (1998) 121-137
16. Jacobson K.K., Morrison L.E., Henderson B.T., Blondin B.A., Wilber K.A., Legator M.S., et al. Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 40 (2004) 19-31
17. Jarvinen T.A., Tanner M., Barlund M., Borg A., and Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26 (1999) 142-150
18. Jarvinen T.A., Tanner M., Rantanen V., Barlund M., Borg A., Grenman S., et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156 (2000) 839-847
19. Kellner U., Sehested M., Jensen P.B., Gieseler F., and Rudolph P. Culprit and victim-DNA topoisomerase II. Lancet Oncol. 3 (2002) 235-243
20. Knoop A.S., Knudsen H., Balslev E., Rasmussen B.B., Overgaard J., Nielsen K.V., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 23 (2005) 7483-7490
21. MacGrogan G., Rudolph P., Mascarel I., Mauriac I., L., Durand M., Avril A., et al. DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer. Br. J. Cancer 89 (2003) 666-671
22. Martin-Richard M., Munoz M., Albanell J., Colomo L., Bellet M., Rey M.J., et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 66 (2004) 388-394
23. Mueller R.E., Parkes R.K., Andrulis I., and O'Malley F.P. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 39 (2004) 288-297
24. O'Malley F.P., Chia S., Tu D., Shepherd L.E., Levine M.N., Huntsman D., et al. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Res. Treat. 24 (2006) 18S
25. O'Malley F.P., Chia S., Tu D., Shepherd L.E., Levine M.N., Bramwell V.H., et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl. Cancer Inst. 101 (2009) 644-650
26. Park K., Han S., Gwak G.H., Kim H.J., Kim J., and Kim K.M. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer. Breast Cancer Res. Treat. 98 (2006) 337-342
27. Petit T., Wilt M., Velten M., Millon R., Rodier J.F., Borel C., et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur. J. Cancer 40 (2004) 205-211
28. Pritchard K.I., Messersmith H., Elavathil L., Trudeau M., O'Malley F., and Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J. Clin. Oncol. 26 (2008) 736-744
29. D. Slamon, W. Eiermann, N. Robert, BCIRG 006:2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by doctaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 neu positive early breast cancer patients. Breast Cancer Res. Treat. 100 (2006) late-breaking abstract 52.
30. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
31. Tinari N., Lattanzio R., Natoli C., Cianchetti E., Angelucci D., Ricevuto E., et al. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin. Cancer Res. 12 (2006) 1501-1506
32. Wolmark N., Wang J., Mamounas E., Bryant J., and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. (2001) 96-102